H1B Salary Data

Home › Employers › Liberty Pharma Inc

Liberty Pharma Inc: H-1B salaries and sponsorship

Liberty Pharma Inc filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $65,583.

Applications (LCAs)4
Certified3
Employer addressLiberty, MO
H-1B dependent employerNo
Median offered salary$65,583
Middle half of salaries$65,582–$110,292
10th–90th percentile$65,582–$137,117

Does Liberty Pharma Inc sponsor H-1B visas?

Liberty Pharma Inc filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Dec 28, 2022. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Quality Assurance Associate3$65,582
Senior Quality Control Chemist1$155,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20234$65,583

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Quality Assurance Associate$65,582–$65,583
Level II
Liberty, MODec 28, 2022Apr 15, 2023Certified
Quality Assurance Associate$65,582–$65,583
Level II
Liberty, MODec 28, 2022Apr 15, 2023Withdrawn
Quality Assurance Associate$65,583–$65,585
Level II
Liberty, MODec 14, 2022Apr 15, 2023Certified
Senior Quality Control Chemist$155,000
Level IV
Liberty, MONov 14, 2022Dec 31, 2022Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).